Arterial Remodeling Technologies (ART) has disclosed new data related to its bioresorbable stent platform that further validates the company's approach to simultaneously balance biocompatibility, biomechanics and bioresorption within a bioresorbable PLA (polylactic acid) stent.

The new data show that the ART stent scaffold can be overinflated by more than 25% without cracking or crazing, and is thus designed to avoid the serious problem of malapposition associated with other bioresorbable stents that was documented at TCT 2010.

ART CEO Machiel van der Leest said these new data underscore another competitive advantage of their bioresorbable stents that are being carefully developed to the specific needs of cardiologists.

Additionally, data reported at TCT 2010 related to other bioresorbable stents in development showed that when these stent struts have been overinflated to compensate for potential malapposition, they have cracked or crazed, and which may lead to another life-threatening coronary event.

ART’s stent is designed to have several competitive benefits over existing bioresorbable stents in development: faster and smoother resorption; a non-crystalline polymer; superior preserved material, without harmful by-products; better, homogeneous stress diffusion; and crack- and crazing-free expansion.

In addition, the ART device is designed to be delivered by conventional stenting techniques, is balloon-expandable and meets the market standard of 6-French compatibility.